Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

This was a randomized, double-blind, placebo-controlled parallel study.

Inclusion Criteria:18 years of age, male or female;History of COVID-19 infection within 1 week;Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and meeting any of the following criteria: With fever, respiratory symptoms; Shortness of breath present,RR ≥30 breaths/min.Clear consciousness, Capable and voluntary informed consent.Exclusion Criteria:Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of the same class, or their excipients, Patients with severe gastrointestinal dysfunction affecting drug absorption;Any person meeting criteria for critical pneumonia;Patients considered unsuitable for this trial by the investigator.